Pharma's Market
SPECIAL REPORT
MOST SHARED
- Stocks Looking Past Europe for a New Driver
- Canaccord, China's Eximbank Plan $1 Billion Resource Fund
- Jobs You Can Do Forever
- DBS Fourth-Quarter Profit Rises 8%; Tops Forecast
- Chart Patterns Suggest Pullback at Hand
- Australia's Newcrest First-Half Underlying Profit Up 17%
- Steelers' Antonio Brown Spends Super Bowl Week with Twitter Fan Turned BFF
- Mulling Buffett's Stock Advice? Get in With REITs: Fund Managers
- UPDATE: Massive Trend Just Getting Underway in Financial Services: Finerman
- LinkedIn Earnings Bode Well for Hiring and Social Media
- Mulling Buffett's Stock Advice? Get in With REITs: Fund Managers
- LinkedIn Earnings Bode Well for Hiring and Social Media
- Top Five Mistakes to Avoid in Online Dating
- Victor Cruz ‘Understands’ Gisele's Super Bowl Frustrations
- Tamminen: The United States of India
- Unusual Volume: Taleo Jumps After Oracle's $1.9 Billion Offer
- Warren Buffett: Stocks Will Outperform Gold and Bonds .. and They're Safer 'By Far'
- So Now You Can’t Give Microsoft Away?
- Robo-Deal Is All About Lowering Mortgage Principal
- The Secret Lives of Traders—Seeking the Next Hot Thing
- Markets Finally Get Greek Deal —So Where's the Rally?
- Warren Buffett: Stocks Will Outperform Gold and Bonds
- Alibaba Plans to Buy Back Yahoo Stake, Go Private
- Greece Deal Fails to Convince, EU Demands More
- 'Mortgage Deal from Hell' Hurts Sound Borrowers: Bove
- Clint Eastwood: Super Bowl Ad Endorses No One
- Zynga, Hasbro Partner to Make Toys, Games
- Home Builder Optimism Up, Industry Expert Says
RSS FEED
FDA's Internet Facelift Still A Work In Progress
Reporter
![]() |
CNBC.com |
They're working on the rest of it and say it'll be completely redone by the end of this year. In the meantime, the site remains difficult to navigate in spots.
I think it's too cluttered, not all that user-friendly, and somewhat counterintuitive when it comes to finding new warnings, communications, etc. in a hurry when I'm on deadline. I look forward to surfing the new-and-improved version when it's finished.
But guess who's quasi-blogging on the new site? Yep, none other than the commish. That's right, Dr. Andrew von Eschenbach has kicked off a weekly online communication, "Andy's Take." You can check out his first installment here.
But it's a one-way thing. This will, no doubt, come as a disappointment to Dendreonians and Provenge proponents among others, but there's no link to email Andy or post comments on his "blog".
You can, however, email me--not with questions for Andy--but with your comments on the blog and all things pharma anytime: .
Time permitting, I'm happy to answer questions about facts, but please don't ask me for buy, sell, hold recommendations because I don't/won't give 'em. Thanks.
Questions? Comments?











